05 May NexPlasmaGen to Present at TiEQuest Summit on May 25, 2026
Montreal / May 4, 2026 – NexPlasmaGen will present its business plan at the TiEQuest Summit 2026 on May 26 from 8:30 AM to 12:30 PM EDT before investors at the Schwartz Reisman Innovation Campus at the University of Toronto.
TieQuest 2026 (TiEQuest 2026 | TiE – Global Entrepreneurship Organization) is a 10-week accelerator and pitch competition designed to help Canadian startups go further and faster. It helps founders refine product-market fit, accelerate growth, and prepare to scale globally. With TiE’s powerful international network, startups gain direct exposure to leading investors in Canada, Silicon Valley, Boston, New York, and India. At TiEQuest, entrepreneurs don’t just compete — they build. Along the way, they access capital, mentorship, and markets, while connecting with leaders who have grown companies on a global scale.
NexPlasmaGen completed phase 1 of this competition, which includes workshops and mentoring, phase 2 elevator pitch, and phase 3 business plan creation. Phase 4 is the Grand Finale at the TieQuest Summit 2026, where participants compete before investors to win a cash prize and investment.
Come in large numbers to this event by visiting TiEQuest Summit 2026 · Luma
ABOUT NEXPLASMAGEN
NexPlasmaGen converges the emerging field of cold plasma biotechnology towards personalized cancer treatment. We develop high-precision cold plasma systems that destroy cancer cells while sparing the healthy tissue. The first application of NexPlasmaGen is the treatment of breast cancer, followed by skin and lung cancer. Its patented cold plasma medical device has the potential to reduce the rate of cancer recurrence as well as side effects and toxicity of the standard of care for the benefit of patients.
Contact :
Dr. Valérie Léveillé, ing., M.Sc.A., CEO/Founder
Tel. : 1-514-229-9458
Email : valerie.leveille@nexplasmagen.com
Website : https://nexplasmagen.com/
No Comments